Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

What is the purpose of this trial?

Brief Summary:

Primary objective:

To evaluate the efficacy of subcutaneous (SC) administration of tralokinumab compared with placebo in treating adolescent subjects (age 12 to <18 years) with moderate-to-severe AD.

Secondary objectives:

To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health-related quality of life compared with placebo.

To investigate the safety, immunogenicity, and tolerability of SC administration of tralokinumab compared with placebo when used to treat adolescent subjects (age 12 to <18 years) with moderate-to-severe AD.


Participation Guidelines

Ages: 12 - 17 years

Gender: Both


LEO Pharma Inc.

Start Date: 09/17/2018

End Date: 07/04/2019

Last Updated: 10/04/2018

Study HIC#: 2000023497

Get Involved

For more information about this study, contact:
Mahin Dawood
+1 203-785-5505
mahin.dawood@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Richard Antaya

Principal Investigator

Sub-Investigators